Showing 2,141 - 2,160 results of 13,522 for search '(( significantly increased decrease ) OR ( significant ((spatial decrease) OR (small decrease)) ))', query time: 0.60s Refine Results
  1. 2141
  2. 2142

    Presentation 1_Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.pptx by Juan Chen (61123)

    Published 2025
    “…</p>Conclusion<p>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.…”
  3. 2143
  4. 2144
  5. 2145
  6. 2146
  7. 2147
  8. 2148
  9. 2149
  10. 2150
  11. 2151

    Comparison of demographic features. by Yueju Cai (20978633)

    Published 2025
    “…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”
  12. 2152

    Data. by Yueju Cai (20978633)

    Published 2025
    “…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”
  13. 2153

    Comparison of examination test and treatment. by Yueju Cai (20978633)

    Published 2025
    “…Additionally, a decrease in birth weight was significantly linked to an increased risk of readmission (OR = 0.998, P = 0.013), although the effect size was relatively small.…”
  14. 2154
  15. 2155
  16. 2156
  17. 2157
  18. 2158
  19. 2159

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 2160

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”